<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476853</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 033</org_study_id>
    <nct_id>NCT00476853</nct_id>
  </id_info>
  <brief_title>Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy</brief_title>
  <official_title>A 48 Week, Randomized, Open-label, 2 Arm Study to Compare the Efficacy, Safety and Tolerability of HAART Containing Nevirapine 400mg/Day Versus Nevirapine 600 mg/Day in HIV-1 Infected Patients Started at 2-6 Weeks After Initiating Rifampin Containing Antituberculous Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>other sponsors:Japanese MOPH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Labor and Welfare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thai MOPH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thai GPO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bamrasnaradura Infectious Diseases Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiang Rai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King Chulalongkorn Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central General Chest Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Research Institute of Tuberculosis (Japan)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 48 week, randomized, open-label, two arm study to compare the efficacy, safety and
      tolerability of HAART containing nevirapine 400 mg/day versus nevirapine 600 mg/day in HIV-1
      infected patients started at 2-6 weeks after initiating rifampicin containing
      antituberculosis therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary data from the HIVNAT PK laboratory indicate that out of 5/60 patients treated
      with nevirapine (200 mg bid) and rifampicin had sub-therapeutic nevirapine levels (&lt;3.0 mg
      mg/L). In a control group of 38 patients using nevirapine without rifampicin there were no
      sub-therapeutic levels. A dose increase of nevirapine while patients who are receiving that
      rifampicin may be required. Both nevirapine and rifampicin are tepatotoxic agents as are
      other agents used in treatment of HIV or tuberculosis. Using a higher nevirapine may prevent
      the occurrence of sub-therapeutic nevirapine levels, but may also induce more liver toxicity.
      To address these issues, we designed a randomized prospective study to evaluate the safety,
      efficacy and pharmacokinetics of nevirapine 400 mg/day versus 600 mg/day with a two weeks
      lead-in 200 mg/day and 400 mg/day respectively, in TB-HIV co-infected patients who taking
      rifampicin and short-term efficacy and toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of nevirapine based HAART 400 mg/day versus 600 mg/day on HIV-1 load as measured by HIV-1 RNA quantification in plasma</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of nevirapine based HAART 400 mg/day versus 600 mg/day</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nevirapine level at week 2, 4 and 12 and 12 hour PK at week 4 (only 20 patients)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune recovery syndrome, adherence, clinical improvement, incidence of new/recurrent AIDS events (CDC class C) between two group</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to mortality or new/recurrent AIDS events (CDC class C), 1 year mortality rate of TB/HIV patients, emerging of ARV resistant especially nevirapine, emerging of anti-TB resistance</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NVP 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NVP 600 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAART containing nevirapine</intervention_name>
    <description>Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed HIV positive after voluntary counseling and testing

          2. Aged 18-60 years of age

          3. Antiretroviral treatment na√Øve.

          4. CD4+ cell count of &lt; 200 cells/mm3 at the time of diagnosed TB

          5. TB is diagnosed and using treatment with rifampin base therapy for at least 2 weeks
             but no longer than 4 weeks duration. The requirement for study entry is at least one
             acid-fast bacillus (AFB) positive smear with a typical syndrome and/or CXR findings
             consistent with pulmonary TB. Pulmonary TB and / or extra pulmonary TB will be
             included if AFB or culture for TB is positive.

          6. No other active OI (CDC class C event)

          7. Negative pregnancy test in females, and willing to use reliable contraception

          8. Able to provide written informed consent.

        Exclusion Criteria:

          1. The following laboratory variables, i. absolute neutrophil count (ANC) &lt; 1000 cells/uL
             ii. hemoglobin &lt; 6.5 g/dL iii. platelet count &lt; 50,000 cells/uL iv. serum AST, ALT &gt; 5
             x ULN vi. serum bilirubin &gt; 2 x ULN vii. serum creatinine &gt; 2 x ULN viii. Pregnant or
             nursing mothers.

          2. Current use of steroid and other immunosuppressive agents.

          3. Current use of any prohibited medications related to compliance and drug
             pharmacokinetics (see appendix )

          4. Acute therapy for serious infection or other serious medical illness (in the judgment
             of the site Principal Investigator) requiring systemic treatment and/or
             hospitalization.

          5. Patients with current alcohol or illicit substance use that in the opinion of the site
             Principal Investigator would conflict with any aspect of the conduct of the trial.

          6. The persons who had been received a mono-therapy of nevirapine

          7. Unlikely to be able to remain in follow-up for the protocol defined period.

          8. Patients with chronic active liver disease.

          9. Patients with proven or suspected acute hepatitis. Patients with chronic viral
             hepatitis are eligible provided ALT, AST &lt; 5 x ULN.

         10. Karnofsky performance score &lt;30%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anchalee Avihingsanon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiangrai Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mae Chan Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phan Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bamrasnaradura Institute</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Chest Hospital</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2007</study_first_submitted>
  <study_first_submitted_qc>May 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <last_update_submitted>June 4, 2010</last_update_submitted>
  <last_update_submitted_qc>June 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Anchalee Avihingsanon</name_title>
    <organization>HIV-NAT</organization>
  </responsible_party>
  <keyword>HIV-TB</keyword>
  <keyword>nevirapine based HAART with rifampin treated TB</keyword>
  <keyword>Compare PK profile, efficacy, safety and tolerability of HAART containing nevirapine 400mg/day versus 600 mg/day in HIV/TB co-infected patients</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

